- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04929041
Testowanie możliwości dodania radioterapii do zwykłego leczenia (immunoterapia z chemioterapią lub bez) u pacjentów z niedrobnokomórkowym rakiem płuca w IV stadium zaawansowania z ujemnym wynikiem PD-L1
Randomizowane badanie fazy II/III nowoczesnej terapii ogólnoustrojowej opartej na immunoterapii z lub bez SBRT w leczeniu zaawansowanego niedrobnokomórkowego raka płuc z ujemnym wynikiem PD-L1
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
- Inny: Quality-of-Life Assessment
- Procedura: Biospecimen Collection
- Biologiczny: Ipilimumab
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Procedura: Echocardiography Test
- Procedura: Positron Emission Tomography
- Biologiczny: Nivolumab
- Promieniowanie: Radiation Therapy
- Procedura: Biopsy Procedure
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Stany Zjednoczone, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Stany Zjednoczone, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Stany Zjednoczone, 92618
- City of Hope at Irvine Lennar
-
Lancaster, California, Stany Zjednoczone, 93534
- City of Hope Antelope Valley
-
Marysville, California, Stany Zjednoczone, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Stany Zjednoczone, 95355
- Memorial Medical Center
-
Napa, California, Stany Zjednoczone, 94558
- Providence Queen of The Valley
-
Sacramento, California, Stany Zjednoczone, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Stany Zjednoczone, 91030
- City of Hope South Pasadena
-
Truckee, California, Stany Zjednoczone, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland, California, Stany Zjednoczone, 91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs, Colorado, Stany Zjednoczone, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Stany Zjednoczone, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Stany Zjednoczone, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Stany Zjednoczone, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Stany Zjednoczone, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Stany Zjednoczone, 80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville, Delaware, Stany Zjednoczone, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Stany Zjednoczone, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stany Zjednoczone, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Stany Zjednoczone, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura, Florida, Stany Zjednoczone, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater, Florida, Stany Zjednoczone, 33756
- Morton Plant Hospital
-
Coral Gables, Florida, Stany Zjednoczone, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Stany Zjednoczone, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Stany Zjednoczone, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Stany Zjednoczone, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Stany Zjednoczone, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Stany Zjednoczone, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven, Florida, Stany Zjednoczone, 33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan, Georgia, Stany Zjednoczone, 30265
- CTCA at Southeastern Regional Medical Center
-
Savannah, Georgia, Stany Zjednoczone, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Stany Zjednoczone, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Stany Zjednoczone, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Northwestern University
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stany Zjednoczone, 60612
- University of Illinois
-
Danville, Illinois, Stany Zjednoczone, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stany Zjednoczone, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Stany Zjednoczone, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stany Zjednoczone, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Stany Zjednoczone, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Stany Zjednoczone, 60426
- Ingalls Memorial Hospital
-
Lake Forest, Illinois, Stany Zjednoczone, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Stany Zjednoczone, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stany Zjednoczone, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Stany Zjednoczone, 60462
- University of Chicago Medicine-Orland Park
-
Rockford, Illinois, Stany Zjednoczone, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Springfield Clinic
-
Springfield, Illinois, Stany Zjednoczone, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Stany Zjednoczone, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point, Indiana, Stany Zjednoczone, 46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames, Iowa, Stany Zjednoczone, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stany Zjednoczone, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Stany Zjednoczone, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Stany Zjednoczone, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stany Zjednoczone, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Stany Zjednoczone, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Stany Zjednoczone, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Stany Zjednoczone, 50266
- Mercy Medical Center-West Lakes
-
West Des Moines, Iowa, Stany Zjednoczone, 50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Stany Zjednoczone, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford, Maine, Stany Zjednoczone, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Stany Zjednoczone, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Stany Zjednoczone, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Chelsea Hospital
-
Flint, Michigan, Stany Zjednoczone, 48503
- Hurley Medical Center
-
Flint, Michigan, Stany Zjednoczone, 48503
- Genesys Hurley Cancer Institute
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Stany Zjednoczone, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Stany Zjednoczone, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Stany Zjednoczone, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stany Zjednoczone, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Stany Zjednoczone, 48764
- MyMichigan Medical Center Tawas
-
West Branch, Michigan, Stany Zjednoczone, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Stany Zjednoczone, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth, Minnesota, Stany Zjednoczone, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, Stany Zjednoczone, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, Stany Zjednoczone, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Stany Zjednoczone, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Stany Zjednoczone, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Stany Zjednoczone, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Stany Zjednoczone, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Stany Zjednoczone, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Stany Zjednoczone, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Stany Zjednoczone, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Stany Zjednoczone, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Stany Zjednoczone, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Stany Zjednoczone, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Stany Zjednoczone, 59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Stany Zjednoczone, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Stany Zjednoczone, 10019
- Mount Sinai West
-
New York, New York, Stany Zjednoczone, 10029
- Mount Sinai Hospital
-
New York, New York, Stany Zjednoczone, 10011
- Mount Sinai Chelsea
-
New York, New York, Stany Zjednoczone, 10075
- Lenox Hill Hospital
-
New York, New York, Stany Zjednoczone, 10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego, New York, Stany Zjednoczone, 13126
- Upstate Cancer Center at Oswego
-
Oswego, New York, Stany Zjednoczone, 13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse, New York, Stany Zjednoczone, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Stany Zjednoczone, 13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse, New York, Stany Zjednoczone, 13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona, New York, Stany Zjednoczone, 13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Stany Zjednoczone, 27609
- Duke Cancer Center Raleigh
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton, Oklahoma, Stany Zjednoczone, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Stany Zjednoczone, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stany Zjednoczone, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Stany Zjednoczone, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Stany Zjednoczone, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Stany Zjednoczone, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Stany Zjednoczone, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Stany Zjednoczone, 17837
- Geisinger Medical Oncology-Lewisburg
-
Reading, Pennsylvania, Stany Zjednoczone, 19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre, Pennsylvania, Stany Zjednoczone, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo, Texas, Stany Zjednoczone, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond, Virginia, Stany Zjednoczone, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stany Zjednoczone, 23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock, Virginia, Stany Zjednoczone, 22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver, Washington, Stany Zjednoczone, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Stany Zjednoczone, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla, Washington, Stany Zjednoczone, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston, West Virginia, Stany Zjednoczone, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland, Wisconsin, Stany Zjednoczone, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Stany Zjednoczone, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Stany Zjednoczone, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, Stany Zjednoczone, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield, Wisconsin, Stany Zjednoczone, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Stany Zjednoczone, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Stany Zjednoczone, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Stany Zjednoczone, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Stany Zjednoczone, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Stany Zjednoczone, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Stany Zjednoczone, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Stany Zjednoczone, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Stany Zjednoczone, 54476
- Marshfield Medical Center - Weston
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Given IV
Inne nazwy:
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo ECHO
Inne nazwy:
Undergo PET
Inne nazwy:
Given IV
Inne nazwy:
Undergo tissue biopsy
Inne nazwy:
|
|
Eksperymentalny: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Inne nazwy:
Undergo blood sample collection
Inne nazwy:
Given IV
Inne nazwy:
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo ECHO
Inne nazwy:
Undergo PET
Inne nazwy:
Given IV
Inne nazwy:
Undergo radiation therapy
Inne nazwy:
Undergo tissue biopsy
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
Ramy czasowe: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
Ramy czasowe: From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Jakość życia
Ramy czasowe: Do 5 lat
|
Do 5 lat
|
|
|
PFS
Ramy czasowe: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
Ramy czasowe: Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
Ramy czasowe: Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Christine M Bestvina, Alliance for Clinical Trials in Oncology
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Choroby płuc
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Rak
- Rak, Bronchogenny
- Nowotwory oskrzeli
- Gruczolakorak płuc
- Nowotwory płuc
- Rak, płuco niedrobnokomórkowe
- Aminokwasy, peptydy i białka
- Białka
- Techniki śledcze
- Lecznictwo
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Procedury chirurgiczne, operacyjny
- Techniki cytologiczne
- Cytodiagnoza
- Czynniki biologiczne
- Zjawiska fizyczne
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Techniki diagnostyczne, chirurgiczne
- Techniki chemii, analityczne
- Analiza widma
- Receptory, powierzchnia komórkowa
- Białka błony
- Antygeny
- Antygeny, powierzchnia
- Biomarkery
- Receptory, immunologiczne
- Antygeny, różnicowanie, limfocyt t
- Antygeny, różnicowanie
- Białka immunologiczne
- Kostymulujące i hamujące receptory komórek T
- Niwolumab
- Ipilimumab
- Radioterapia
- Promieniowanie
- Biopsja
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Antygen CTLA-4
Inne numery identyfikacyjne badania
- NCI-2021-06042
- U10CA180821 (Grant/umowa NIH USA)
- NCI-2021-06042 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- A082002 (Inny identyfikator: CTEP)
- A082002 (Inny identyfikator: Alliance for Clinical Trials in Oncology)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .